Cambridge, 27th February 2014. Eagle Genomics Ltd., an expert provider of bioinformatics software and services across a wide range of the life science and other sectors, has announced a change in leadership as it continues its international growth.
Following on from a successful £1m investment round in late 2013, Eagle has expanded its Life Sciences R&D data management services and has a growing number of blue-chip clients. Dr David Flanders joined the company as CEO more than two years ago to raise equity for growth, to support organisational development, enable business scale up, and drive the development of Eagle’s new R&D collaborative platform, ElasticAP. Having achieved his targets and placed Eagle in an excellent position to move forward, David is now moving on to his next challenge. David has also overseen the recruitment of a number of key new senior staff to enable technical and business development.
As David moves on, Founder and COO Abel Ureta Vidal takes on the mantle of Acting CEO with the full support of his executive team and Eagle’s board.
Eagle’s Chairman Alan Barrell said: “I have confidence in the future growth of the company in the expanding Life Science Big Data market, and I would like to thank David for leading the team in their continuing efforts which have placed Eagle in a prime position to exploit fast growing global opportunities. More than 70% of Eagle’s business is already outside the UK and a significant proportion is in the USA – the world’s biggest market for its products and services.”